INTRODUCTION
Cancer chemotherapy is an integral component of cancer therapy. Although not considered curative, advances in drug discovery, targeted therapy, and the improved characterization of the PK (PK) and PD (PD) properties of anticancer drugs indicate drug treatment will be a critical cornerstone in the war on cancer. Drugs fail in cancer patients for numerous reasons that in some cases can be attributed to PK and PD failures such as the development of drug resistance and inadequate tumor drug concentrations. 1 , 2 It is generally assumed that pharmacological effects are related to the drug concentration in a target tissue. Since the relationship between plasma concentrations and pharmacological effects has been successfully defi ned for a variety of medications in different therapeutic classes, plasma concentrations are commonly used as a surrogate for drug concentrations at other sites. 3 However, the microenvironment within tumors is signifi cantly different from that within normal tissues. Many factors such as heterogeneous tumor blood fl ow, vascular permeability, and cell density, as well as increased interstitial pressure, may hamper the penetration and delivery of drugs from plasma into the tumor and distribution within the tumor, leading to complex relationships between concentrations in plasma, interstitium, and neoplastic cells. [4] [5] [6] Therefore, given the complexities of drug accumulation in tumors, it is likely that tumor-specifi c drug concentration measurements will be of greater value, compared with plasma drug concentrations, as an indicator of drug action and clinical response.
Preliminary evidence has suggested that concentrations of chemotherapeutic drugs in a tumor may correlate with the response to chemotherapy. 7 , 8 Therefore, it would be ideal if the time course of a given drug and/or its metabolite(s) could be determined in tumors. Initially, this task was often approached by analysis of drug concentrations in tumor homogenates, which involved killing a series of animals at multiple discrete time points following drug administration. 9 Besides considerable resources needed to conduct such studies, the main drawback of this postmortem technique is that drug concentrations determined in tumor homogenates only refl ect an average of vascular, interstitial, and intracellular drug concentrations, which invariably limit evaluation of site-specifi c phenomenon.
Recently, noninvasive techniques including positron emission tomography (PET) 10 , 11 and magnetic resonance spectroscopy (MRS) 12 , 13 have been adopted to allow the intensity and duration of tumor exposure to therapeutic agents to be monitored continuously in a single animal. However, those noninvasive alternatives are not readily available and may not offer either the desired sensitivity, or specifi city.
The development of microdialysis has provided researchers with a specifi c tool to sample extracellular spaces for endogenous and exogenous compounds. This in vivo sampling technique is based on the passive diffusion of substances across a semipermeable membrane, which is usually fashioned into a probe so that the interior of the probe can be perfused with a suitable carrier solution. 14 , 15 Microdialysis was originally developed to allow in vivo sampling of neurotransmitters in the brain. 16 Over the last decade, in vivo microdialysis has found increasing application in PK and drug metabolism studies, particularly in the area of monitoring drug disposition at peripheral tissue sites; microdialysis probes can be placed in virtually any tissue, organ, or biological fl uid, and the collected fractions can be analyzed by the use of the most suitable analytical techniques. 17 , 18 There is growing interest in using microdialysis methodology to evaluate the disposition of anticancer agents in tumor xenografts and in patients with accessible tumors. [19] [20] [21] Sampling by this technique has several advantages over the postmortem and noninvasive imaging techniques mentioned above. First, continuous sampling can be performed in a single animal subject over a prolonged period, thereby allowing fewer animals to be used and minimizing the interanimal variability. Second, only extracellular protein-unbound or active drugs in the direct vicinity of neoplastic cells are sampled and measured. Free drug concentrations in the interstitial compartment determined over time can readily support the development of physiologically based PK models. Third, microdialysis sampling can be used for a broad range of substances, including the majority of small molecules and some macromolecules, in contrast with noninvasive techniques, which are often limited by low spatial resolution, high costs associated with the synthesis of radiolabeled compounds, and the performance of imaging studies.
In the following review, considerations of using microdialysis methodology for PK and PD studies are examined with an emphasis on its application to understanding drug disposition and response in solid tumors. In addition, potential advances offered by microdialysis that may be applied to problems in PK and PD research of anticancer drugs are discussed.
CONSIDERATIONS OF USING MICRODIALYSIS METHODOLOGY FOR PHARMACOKINETIC STUDIES

Recovery
It has long been recognized that drug equilibration across the microdialysis membrane, separating interstitial fl uid and the perfusion medium, is a dynamic process and requires a calibration technique to estimate actual interstitial fl uid drug concentrations. 22 , 23 This combined with other factors indicates that microdialysate concentrations of a substance refl ect only a fraction of the unbound concentrations in the extracellular fl uid surrounding the implanted probe. The ratio of the microdialysate concentration to the actual interstitial concentration of a substance is defi ned as relative recovery, while the total amount recovered per time unit is termed absolute recovery. 24 Determination of absolute recovery may be enough to make valid comparisons between the data obtained. However, if accurate estimations of extracellular concentrations are desired, relative recovery has to be determined. Both in vitro and in vivo methods have been used to assess relative recovery in microdialysis experiments. [25] [26] [27] [28] [29] [30] [31] [32] [33] The main determinants of in vitro and in vivo recoveries are summarized in Table 1 . In addition to the main factors that infl uence the in vitro recovery, such as membrane properties, perfusate fl ow rate, and physicochemical properties of the analyte, the in vivo performance of a microdialysis probe is also dependent on the surrounding tissue properties and the interaction between the analyte of interest and the tissue to be sampled. [34] [35] [36] In this regard, results from the in vivo method are more reliable and allow better estimation of actual extracellular concentrations of a given analyte as compared with those from the in vitro method.
In vivo calibration
To date, various in vivo calibration methods have been used to assess relative recovery in in vivo microdialysis experiments. Among those established methods, the simplest one is retrodialysis. This technique is based on the assumption that the mass transport effi ciency over the membrane is the same in both directions, and that recovery is independent of the perfusate concentrations 32 :
(1) R R = 1 − C o u t C i n where RR RR is the relative recovery, C in is the analyte concentration in the perfusate, and C out is the analyte concentration in the dialysate. R R = 1 − C o u t C i n , The further elaboration of the retrodialysis method is retrodialysis using an internal reference, which consists of adding a marker to the perfusate. 27 , 29-31 The marker should be a compound with diffusion characteristics close to the analyte 
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of interest. The recovery is determined by measuring the relative loss of the analyte diffusing from the perfusate into the extracellular fl uid (ECF). Application of this method may be hindered by the availability of a substance with diffusion properties similar to the analyte, and the potential competition or interference of the internal standard with the disposition of the analyte.
A more comprehensive method for the in vivo calibration introduced by Lönnroth et al 25 is the zero net fl ux method, which is based on the principle that the net direction of diffusion over the microdialysis membrane follows the concentration gradient. This method, which consists of the determination of mass transport of the analyte across the microdialysis membrane as a function of perfusate concentrations, is often found to be time-consuming as it requires steady-state conditions:
where C m is the concentration of the extracellular fl uid surrounding the dialysis probe, which is given by the intercept on the C in -axis of the C in -C out versus C in plot.
The " zero fl ow " method is another comprehensive method used to estimate extracellular concentrations at steady-state by extrapolation of dialysate concentrations at various fl ow rates to the concentration at zero fl ow. 37 This method possesses about the same advantages and disadvantages as the zero net fl ux method.
R R = 1 − e − k Φ where k is a constant and Φ is the fl ow rate of the perfusate. ( 3 ) R R = 1 − e − k Φ , Approaches other than the above-mentioned methods have also been used for in vivo calibration of microdialysis probes 25 , 26 , 28 ; however, all methods suffer one or more disadvantages. Therefore, the choice of an appropriate calibration method should be made based on the specifi c study design to ensure accurate estimation of the microdialysis probe recovery.
Recovery of macromolecules
The utility of the microdialysis technique is not limited to sampling small molecules. The current development of larger molecular weight cutoff microdialysis probes (up to 100 kDa) has made it possible to sample macromolecules, including certain proteins, which can act as valuable markers of drug response. However, increased porosity of the semipermeable membrane can quickly cause a solution balance problem. In other words, the membrane becomes more susceptible to water loss due to osmotic fl ux. 17 , 36 To counteract this osmotic fl ux, an osmotic agent can be added into the perfusate as a means to counterbalance the transmembrane hydrostatic driving pressure.
In a study by Trickler and Miller, 38 bovine serum albumin (BSA) was used as an osmotic agent in the perfusate to prevent the fl uid loss from the microdialysis probe when attempting to dialysis molecules of up to 53 kDa. By adjusting the BSA content of phosphate-buffered saline (PBS) as a function of the fl ow rate of the perfusate, fl uid loss due to convective fl ow out of the probe was completely abolished. Moreover, the addition of BSA to the perfusate improved the in vitro recovery of 2 cytokines being tested (ie, interleukin-1 beta [IL-1B] and rat tumor necrosis factor [TNF]) with the molecular weight of 17.3 and 53 kDa, respectively.
Another osmotic agent often used to improve recovery of macromolecules is dextran. In a study by Dabrosin et al, 39 with the addition of 4% (wt/vol) of dextran, the mean recovery of vascular endothelial growth factor (VEGF) at room temperature was 6% at a fl ow rate of 0.6 μ L/min. The amount of VEGF present in the microdialysate collected in vivo was well above the lower limits of quantitation of an enzymelinked immunosorbent assay (ELISA). Similarly, by using a perfusate containing Ringers Dextran 60 40 or dextran-70, 41 reliable sample volume and high analyte recovery were achieved by Sjogren et al 40 for the in vivo microdialysis determination of interleukin-6 in human dermis.
Invasiveness of Microdialysis Probe Implantation
Microdialysis is an invasive technique and has the potential to cause adverse tissue reactions that may infl uence the measurements and interpretation of the data. The invasiveness of peripheral microdialysis has been examined in different tissues, including dermis, 42 liver, 43 muscle, and tumor. 44 The extent of tissue damage due to probe implantation was evaluated by histological examination as well as by microdialysis delivery studies. Expected acute infl ammatory response was observed in dermis, liver, and muscle, with the initial invasion of neutrophils followed by macrophages, which generally had no effect on the performance of the implanted microdialysis probes. [42] [43] [44] For intracerebral microdialysis, the perturbation in normal blood-brain barrier (BBB) transport function by the implantation of guide cannulas and/or microdialysis probes may lead to overestimation of the rate of transfer into and out of the brain. [45] [46] [47] One way to attenuate the damage may be to leave a few days for experimental animals to reestablish the barrier properties before microdialysis is conducted. Even in the event of tissue damage that could alter analyte recovery, a comparative study design should negate such effects as each treatment group would be similarly affected.
APPLICATION OF MICRODIALYSIS IN INVESTIGATION OF DRUG DISPOSITION IN TUMOR
Quantifi cation of drug delivery to the tumor tissue using microdialysis is an attractive way to assess if suffi cient E662 amounts of anticancer drugs can reach their targets. Our previous review has provided comprehensive information on the potential applications of microdialysis in characterization of drug disposition in tumor. 19 In the present review, we provide an overview of representative studies published over the past 5 years and highlight the contributions of microdialysis technique to the development of physiologically based PK models, which may eventually predict anticancer drug concentrations in human tumors.
Preclinical Studies
Microdialysis has seen extended applications in preclinical PK studies aimed to characterize tumor disposition of both conventional and novel antineoplastic agents, [48] [49] [50] [51] [52] [53] evaluate novel formulations, 54 and scrutinize potential drug-drug interactions at the site of action in a wide range of tumor models. 55 , 56 Microdialysis has been used to characterize local distribution in brain tumors of 4-pyridoxate diammine hydroxy platinum (PyPt), a novel cisplatin derivative, using rats implanted with 9L glioma. 53 In this study, 2 microdialysis probes were placed so that microdialysates from ECF in tumor and normal brain tissues could be collected simultaneously. By using this dual-probe approach, tissue disposition of the drug in both tumor and neighboring normal regions can be examined in the same brain, and comparative drug disposition data obtained from the same animal. The result of this study showed that unbound platinum (Pt) released from PyPt insuffi ciently penetrated the BBB into normal interstitial space, whereas the uptake of unbound Pt in the 9L glioma was signifi cantly higher than that in the normal brain tissue owing to the compromised BBB.
Although it was not determined, it would be assumed for accurate comparison of the data from these 2 sites that implantation trauma would be equivalent in normal brain and brain tumor. Barring the technical diffi culties of performing microdialysis at multiple sites in the brain, the strategy is appealing.
The ability of microdialysis sampling to selectively quantify drug disposition in tumors renders it a unique approach that can provide valuable information on drug delivery systems, drug interactions, and drug transport. Zamboni et al 54 measured the unbound (Pt) concentrations in tumor interstitium from 2 probes placed in both right and left side of the tumor after administration of cisplatin and its 2 different liposomal formulations, SPI-077 and SPI 077 B103, to 3 groups of mice bearing B16 murine melanoma tumor, respectively. The peak concentrations of total Pt measured in tumor homogenates were 2.2-to 5-fold higher after administration of SPI-077 and SPI-077 B103 than after administration of cisplatin. The time-to-peak concentrations of total Pt in tumor were longer after administration of SPI-077 (48 hours) and SPI-077 B103 (96 hours) than after administration of cisplatin (0.5 hours). However, there was no detectable unbound Pt in the tumor ECF after administration of SPI-077 and SPI-077 B103, whereas unbound Pt concentrations were detectable in the ECF of all tumors after administration of cisplatin. In addition, the peak concentrations of Pt-GG and Pt-AG DNA adducts were 3.7-and 6.2-fold lower after administration of SPI-077 and SPI-077 B103 than after administration of cisplatin. These results suggest that SPI-077 and SPI-077 B103 are able to distribute into tumor and lodge in the interstitial spaces among tumor cells but release very little unbound Pt into tumor ECF or into tumor cells to form Pt-DNA adducts. This fi nding was in agreement with that in a phase 1-2 study of SPI-077 in patients with inoperable head and neck cancer, showing that only 2 of 18 patients had partial responses to SPI-077 with 2 responses in 29 evaluated sites in spite of the absence of dose-limiting toxicity. 57 This study demonstrated the ability of microdialysis measurements to distinguish what material is available at the tumor and provided a mechanistic foundation to help interpret clinical observations.
Treatment with cytotoxic drugs in conjunction with angiogenic inhibitors represents a paradigm for combination of antineoplastics with different mechanisms of action and nonoverlapping toxicities to enhance responses to cancer treatment and attenuate the development of drug resistance. Some studies have reported that angiogenic agents may decrease tumor uptake of the co-administrated anticancer drugs by reducing microvessel density and capillary permeability, 55 , 58 , 59 whereas others have shown that antiangiogenic therapy may enhance cytotoxic chemotherapy by restoring capillary architecture and decreasing interstitial fl uid pressure and hypoxia. 56 , 60 Several publications from the laboratory of J. Gallo have reported the use of microdialysis in evaluating the potential drug interactions between angiogenic inhibitors and cytotoxic drugs at the target site. 55 , 56 , 58 , 59 Based on the previous fi nding that the interstitial fl uid concentration of temozolomide (TMZ), a DNAalkylating agent, was signifi cantly decreased in the presence of TNP-470, an antiangiogenic agent, in a rat C6 glioma subcutaneous (sc) model, 59 a further study was performed using xenograft models that differentially expressed VEGF to evaluate the TMZ:TNP-470 drug interaction in both sc and intracerebral gliomas. 55 Probe calibration in vivo for this study was achieved by the method of zero-fl ow. Consistent with the previous study, it was shown that, in both the sc and intracerebral VEGF-overexpression tumor models, TNP-470 treatment produced signifi cant reductions in TMZ tumor concentrations and tumor:plasma concentration ratios compared with control, being reduced an average of 25% and 50% in the sc and intracerebral tumors, respectively. However, in another study that was designed to extend the same concept by the use of another angiogenic inhibitor, SU5416, a specifi c receptor tyrosine kinase inhibitor of VEGF receptor 2, a paradoxical effect of SU5416 on the tumor disposition of TMZ in sc and intracerebral tumors was observed [56] . In sc tumors, SU5416 treatment produced a 24% reduction in steady-state TMZ tumor concentration ( C t ) values ( P < .05) as well as 21% reductions in tumor/ plasma concentration ratios ( C t / C p ; p = 0.11) compared with control. In intracerebral tumors, steady-state TMZ C t and C t / C p ratios were signifi cantly increased by 2-fold in the SU5416 treatment group compared with control. A possible explanation that may pertain to this differential result is the microdialysis sampling site, peripheral versus central, which may be enhanced by the ability of the dimethyl sulfoxide administration vehicle to cause tumor necrosis. Regardless of the discrepancy between the results obtained from TMZ:TNP-470 and TMZ:SU5416 drug interaction investigations, the importance of using microdialysis to evaluate drug interactions between antineoplastics at the target site has been established. Based on the important information, additional work is needed to develop PK-PD strategies to identify optimal combination regimens of angiogenesis inhibitors and cytotoxic drugs.
Clinical Studies
The clinical use of microdialysis technique to evaluate drug disposition in tumors is of considerable interest with the recognition that insuffi cient drug penetration into the interstitium of solid tumors represents a rate limiting step in clinical response to chemotherapy. However, relatively few studies have hitherto been performed in a clinical setting owing to both ethical and methodological considerations. Nonetheless, microdialysis has been used to evaluate the tumor disposition of some commonly used anticancer drugs, including 5-fl uorouracil (5-FU), 7 capecitabine, 20 cisplatin, 61 dacarbazine, 62 and methotrexate, 63 , 64 in patients with accessible tumors, such as breast cancer, melanoma, and oral cancer.
In a study of Mader et al, 20 microdialysis probes were implanted into a cutaneous metastasis and subcutaneous connective tissue to evaluate the interstitial tissue PKs of capecitabine and its metabolites in breast cancer patients with skin metastases. Probe calibration for capecitabine and 5-FU was performed in both healthy and tumor tissues according to an in vivo retrodialysis procedure. The recovery of capecitabine was found to be similar to that of 5-FU in both tissues. The exposure to capecitabine in the malignant lesions was signifi cantly higher compared with plasma, whereas the area under the curve (AUC) of all other me tabolites including 5 ′ -deoxy-5-fl uorocytidine (DFCR), 5 ′ -deoxy-5-fl uorouridine (DFUR), and 5-FU did not differ signifi cantly between metastatic tumors and plasma. These results were in accordance with those obtained previously by Schüller et al, who measured 5-FU levels in tumor biopsies and reported a mean tumor/plasma ratio of 21 for 5-FU in patients with colorectal tumors. 65 With regard to tissue exposure at the extracellular level, there was no signifi cant difference between malignant and healthy tissues, suggesting little selectivity among both types of tissues.
Microdialysis has been employed to compare a standard high-dose intra-arterial (IA) cisplatin chemotherapy with a novel treatment approach, so-called crystalline cisplatin embolization, in which cisplatin is administered as a highly concentrated cisplatin crystalline suspension in combination with intravenous infusion of sodium thiosulfate (STS), a cisplatin neutralizer, in patients with oral cancer. 61 Tumor concentrations of both free cisplatin and STS were determined using microdialysis. Probe recoveries were only estimated in vitro because as the authors mentioned, prolongation of tumor dialysis was not tolerable for the patients due to restrictions of speaking, drinking, and eating during the dialysis period. It has been found in this study that crystalline cisplatin embolization yielded ~5-fold higher tumor cisplatin levels than the standard IA perfusion. Moreover, in contrast to cisplatin IA perfusion, cisplatin embolization appeared to meet 2 PK prerequisites for optimal response and low toxicity on the basis of the systemic and intratumoral molar STS/cisplatin ratios, which should be greater than 500 outside the tumor to neutralize cisplatin, and lower than 100 within tumors to avoid a loss of tumor cell killing. 66 It was concluded that this study provided a PK basis for the superselective high-dose IA cisplatin regimen combined with intravenous STS for neoadjuvant treatment of oral cancer and suggests that the novel cisplatin embolization approach is superior to IA cisplatin perfusion.
To examine if the therapeutic failure in tumor therapy is attributed to an impairment of transcapillary drug transfer into solid tumor, Joukhadar et al 62 employed microdialysis sampling for measuring dose intensity of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide (AIC) in cutaneous malignant melanoma metastases as well as subcutaneous adipose tissue after intravenous administration of dacarbazine at doses of 200 to 1000 mg/m 2 in patients with metastatic malignant melanoma (MMM). Microdialysis probe recovery of dacarbazine was determined using in vivo retrodialysis method. The results of this study showed that AUC values for dacarbazine and AIC measured in plasma correlated closely with corresponding AUC values measured in the ECF of MMMs, suggesting favorable tumor penetration characteristics of dacarbazine and its active metabolite AIC. This fi nding indicates that the poor response to antineoplastic therapy with dacarbazine may be to the resistance of melanoma cells at a molecular level, and not necessarily an inability of dacarbazine and AIC to penetrate into the interstitium of MMM.
Pharmacokinetic Modeling
Traditional PK models concern themselves with the disposition of a large mass of drug in the entire body, while disposition of little mass in a specifi c site is not described. Heterogeneous tumor drug distribution further diminishes the hope that kinetics of drug in plasma will parallel that in tumor. Therefore, a PK model including a tumor compartment that is relatively closely associated with the pharmacological effect may provide enhanced insight not only into drug transport but also into pertinent PK-PD relationships.
Zamboni et al 50 proposed a 2-compartment model with uncoupled distribution of the plasma and tumor compartments, which was used to fi t to the plasma and tumor ECF concentration-time profi les of unbound Pt after cisplatin administration to tumor-bearing mice. The authors stated that it was impossible to obtain accurate estimates of the rate constant describing the movement of drug into the tumor ECF or the volume of the ECF by modeling the plasma and tumor distribution simultaneously owing to the 100-to 1000-fold difference between the rate constants describing systemic and tumor disposition of unbound Pt. Therefore, the tumor disposition of drug was modeled separately from the systemic disposition. The following differential equation was used to defi ne the rate of change of unbound Pt concentration in tumor ECF:
where C ECF is the concentration of unbound Pt in the tumor ECF, k P-ECF is the rate of transfer of unbound Pt from plasma into tumor ECF, k ECF-P is the rate constant of transport of unbound Pt out of tumor ECF, V ECF is the volume of tumor ECF, and A p is the fi tted exponential function describing the amount of unbound Pt in the plasma.
Another model proposed by Zamboni et al 67 was a 3-compartment PK model, which consisted of a central, a peripheral, and a tumor compartment and was used to describe topotecan plasma and tumor ECF disposition in a human neuroblastoma model. In this study, serial sacrifi ce designs were used to collect blood samples, while serial microdialysate samples were collected over a time period of 5 hours from freely-moving mice bearing human neuroblastoma xenografts. Plasma concentrations of topotecan were modeled simultaneously with the tumor ECF concentrations. The volume of the tumor compartment was set at 5 mL/m 2 as estimated by volume displacement.
Physiologically based hybrid PK models have been recently developed by the Gallo group. 68 Such models coupled a forcing function, an equation describing the plasma drug concentration-time profi le, with a model describing drug disposition in tumors. The great potential of this hybrid model approach lies in its ability to predict drug disposition in human tumors based on the preclinical (tumor disposition) and clinical (forcing function) data. Of the 2 hybrid models proposed in this study, the hybrid model derived from a preclinical study of temozolomide disposition in tumors was able to include a 3-compartment tumor model that depicted vascular, interstitial fl uid, and intracellular subcompartments due to the availability of tumor ECF drug concentrations. This structure introduces tumor blood fl ow and physiologic volumes into the model that provides not only a means to assess how these parameters impact on drug disposition but that also can be readily replaced with human data when the hybrid model is applied to humans.
APPLICATION OF MICRODIALYSIS IN ASSESSMENT OF CHEMOTHERAPEUTIC RESPONSE
Microdialysis sampling can be employed to assess chemotherapeutic responses or toxicities by monitoring changes in the concentration of one or more endogenous compounds in the target tissue. In a clinical study by Castejon et al, 69 microdialysis was used to determine the levels of free 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) in blood after administration of cisplatin in cancer patients as 5-HT is known to be involved in the production of emesis associated with cisplatin treatment. The previously determined in vivo recoveries of the intravenous microdialysis probes for 5-HT and 5-HIAA averaged 98.6%. 70 The results from this study showed that the increases in free 5-HIAA levels in blood were associated with increases in urinary 5-HIAA, and these increases occurred at times at which acute emesis is known to develop after cisplatin. Although similar results were not found for 5-HT, it is suggested that the circulating 5-HIAA levels represent the metabolism of 5-HT either within the gut or on its passage through the liver after being released from the gut, and thus can be used as a marker of free 5-HT within the intestinal wall that is involved in triggering the emetic response after cisplatin chemotherapy.
Although microdialysis is at its best for small molecules, the availability of microdialysis probes with higher molecular weight membrane cutoff has made it possible to sample biologically relevant macromolecules. Garvin and Dabrosin 71 examined the effect of tamoxifen on the secretion of VEGF in a mouse model of human MCF-7 breast cancer using microdialysis to sample VEGF in the tumor interstitium, where VEGF is biologically active. The results from this study showed that tamoxifen signifi cantly decreased the extracellular VEGF in solid MCF-7 tumors but increased intracellular VEGF. Microdialysis played a critical role in this study compared with the other techniques, such as western blot of the tumor homogenate and immunohistochemistry of tumor sections, which were unable to detect extracellular VEGF specifi cally. The same approach has E665 also been successfully applied in a clinical study to investigate the variability of VEGF in normal human breast tissue in vivo during the menstrual cycle. 72 Given the fact that the extracellular space is the bioactive site for the majority of growth factors associated with tumor growth, using microdialysis to sample growth factors at extracellular spaces opens the possibility to monitor tumor response to growth factor-targeting chemotherapy. Moreover, if the time course of such responses could be quantifi ed by the use of microdialysis and integrated with the PK profi les of the corresponding drug, it would help to defi ne the PK-PD relationship, which is essential for the rational design of drug administration regimens in cancer patients.
CONCLUSIONS
The ability of in vivo microdialysis to measure the chemical composition of the ECF has provided an important tool enabling the determination of tumor drug concentrationtime profi les. The information on drug disposition in tumors may help to defi ne not only drug transport but also pertinent PK-PD relationships that could aid to select appropriate drug candidates and to design optimal dosing regimens. It is hoped that with the increasing acceptance of microdialysis as a well-validated sampling technique, the application of microdialysis in the development of anticancer drugs will become the norm. The application of microdialysis for evaluating tumor response to chemotherapy has not been fully established as yet. Nonetheless, with the commercial availability of large molecular weight cut-off microdialysis probes, microdialysis approach is expected to offer exciting potential for defi ning concentration-effect relationships for anticancer drugs.
